In this study, we found that TF effectively reduces the proliferation of A1207 glioblastoma cells with an EC<sub>50</sub> value of 13.7 μM, which is equal to the EC<sub>50</sub> value of CX-4945, which was the first CK2 inhibitor in clinical phase II trials (13.9 μM). The gene discussed is TF; the disease is glioblastoma.